Next Article in Journal
Crossing the Border: Molecular Control of Motor Axon Exit
Next Article in Special Issue
Loop-Mediated Amplification Accelerated by Stem Primers
Previous Article in Journal
Caffeine Abolishes the Ultraviolet-Induced REV3 Translesion Replication Pathway in Mouse Cells
Previous Article in Special Issue
Applications of Next-Generation Sequencing Technologies to Diagnostic Virology
Int. J. Mol. Sci. 2011, 12(12), 8530-8538; doi:10.3390/ijms12128530

Biochip-Based Detection of KRAS Mutation in Non-Small Cell Lung Cancer

1 ViennaLab Diagnostics GmbH, 1120 Vienna, Austria 2 Molecular Oncology Group, Department of Obstetrics and Gynecology, Medical University Vienna, 1090 Vienna, Austria 3 Ludwig Boltzmann Gesellschaft, Cluster Translational Oncology, 1090 Vienna, Austria 4 Division of Oncology, Department of Internal Medicine I, Medical University of Vienna, 1090 Vienna, Austria 5 Department of Cardiothoracic Surgery, Medical University of Vienna, 1090 Vienna, Austria
* Author to whom correspondence should be addressed.
Received: 18 September 2011 / Revised: 17 November 2011 / Accepted: 17 November 2011 / Published: 29 November 2011
(This article belongs to the Special Issue Advances in Molecular Diagnostics)
View Full-Text   |   Download PDF [239 KB, uploaded 19 June 2014]   |   Browse Figure


This study is aimed at evaluating the potential of a biochip assay to sensitively detect KRAS mutation in DNA from non-small cell lung cancer (NSCLC) tissue samples. The assay covers 10 mutations in codons 12 and 13 of the KRAS gene, and is based on mutant-enriched PCR followed by reverse-hybridization of biotinylated amplification products to an array of sequence-specific probes immobilized on the tip of a rectangular plastic stick (biochip). Biochip hybridization identified 17 (21%) samples to carry a KRAS mutation of which 16 (33%) were adenocarcinomas and 1 (3%) was a squamous cell carcinoma. All mutations were confirmed by DNA sequencing. Using 10 ng of starting DNA, the biochip assay demonstrated a detection limit of 1% mutant sequence in a background of wild-type DNA. Our results suggest that the biochip assay is a sensitive alternative to protocols currently in use for KRAS mutation testing on limited quantity samples.
Keywords: non-small cell lung cancer; KRAS; mutation detection; biochip hybridization non-small cell lung cancer; KRAS; mutation detection; biochip hybridization
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
MDPI and ACS Style

Kriegshäuser, G.; Fabjani, G.; Ziegler, B.; Zöchbauer-Müller, S.; End, A.; Zeillinger, R. Biochip-Based Detection of KRAS Mutation in Non-Small Cell Lung Cancer. Int. J. Mol. Sci. 2011, 12, 8530-8538.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here


Cited By

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert